Solid Biosciences Updates on SGT-001 Phase I/II Clinical Hold for IGNITE DMD Program

May 7, 2020

Earlier today, Solid Biosciences a press release following receipt of written communication from the FDA regarding the clinical hold placed on their IGNITE DMD Phase I/II clinical trial. Please read their community letter below or click the links below to view their full response.

Community Letter:

Press Release:

Dear Duchenne Community,

Since day one, we have been focused on working to develop meaningful therapies for patients with Duchenne muscular dystrophy. This cause is deeply embedded into every fiber of Solid Biosciences, which was founded by individuals impacted by Duchenne. Our commitment remains unwavering.

As you may recall, the Food and Drug Administration (FDA) placed a hold on our IGNITE DMD Phase I/II clinical trial in November 2019, following a serious adverse event (SAE) in the last patient dosed. As we announced in December, the child fully recovered, and all clinical study patients continue to be monitored.

In April 2020, Solid submitted a response to the FDA that included changes to the clinical protocol designed to enhance patient safety, as well as information related to improvements to our manufacturing process. The FDA has responded by maintaining the clinical hold and requesting further data and analyses relating to this manufacturing process. We are in the process of generating these data and expect to submit this information to the FDA before the end of the third quarter of 2020.

We share the FDA’s commitment to patient safety and are working collaboratively with the agency to resolve the clinical hold. We consider patient safety our utmost priority. We believe the clinical development of SGT-001 could offer meaningful benefits to patients with this devastating disease.

We want to thank all patients and families who commit to participate in clinical trials and recognize the decision to do so is not made lightly. As always, we are grateful for your trust and support in our mission to advance meaningful therapies for the community that we serve. We are looking forward to providing you with further updates in the near future.


Your Solid Biosciences Team
[email protected]

Experience the magic this summer!

How is the rare disease community accomplishing goals?

Tune in on February 29 to hear from our panel and moderators on how they are accomplishing goals and living life to the fullest!

Your gift helps Jett Foundation provide programming and opportunities, such as Camp Promise, to many families impacted by Duchenne muscular dystrophy each year.

Accessible Vehicle Fund Applications Open